

Can't fill your Breo Ellipta prescription? Learn about proven ICS/LABA alternatives like Advair, Symbicort, and Wixela Inhub for asthma and COPD.
If you've been prescribed Breo Ellipta (fluticasone furoate/vilanterol) for asthma or COPD and your pharmacy can't fill it — whether due to stock issues, insurance restrictions, or cost — it's natural to feel worried. After all, consistent use of your maintenance inhaler is critical for controlling your symptoms and preventing flare-ups.
The good news is that several effective alternatives exist in the same drug class. In this article, we'll explain how Breo Ellipta works and walk you through the most common alternatives your doctor might consider.
Breo Ellipta is a combination inhaler containing two active ingredients:
Together, these ingredients address both the underlying inflammation and the airway tightness that cause breathing difficulties in asthma and COPD. Breo Ellipta's key advantage is its once-daily dosing, which makes it convenient and can improve medication adherence.
It comes as a dry powder inhaler in two strengths: 100/25 mcg (for asthma and COPD) and 200/25 mcg (for asthma only). For a full overview of the medication, see our guide: What Is Breo Ellipta? Uses, Dosage, and What You Need to Know.
All of the alternatives below are ICS/LABA combination inhalers — meaning they work through the same basic mechanism as Breo Ellipta. However, they differ in specific ingredients, dosing frequency, inhaler device type, cost, and availability.
Important: Never switch medications on your own. Always talk to your doctor or prescriber before making any changes to your inhaler therapy.
Wixela Inhub is an authorized generic version of Advair Diskus — and it's one of the most affordable ICS/LABA options available today.
Wixela Inhub is often the first alternative insurers suggest through step therapy programs. The main difference from Breo Ellipta is that it requires twice-daily dosing instead of once daily.
Advair is one of the most well-known respiratory medications in the world and was the predecessor to Breo Ellipta.
If you've used Breo Ellipta, you'll find the Diskus device somewhat familiar, though not identical to the Ellipta inhaler.
Symbicort is another popular ICS/LABA combination that uses a metered-dose inhaler (MDI) rather than a dry powder device.
Symbicort may be a good option if you prefer or do better with an MDI device rather than a dry powder inhaler. Formoterol also has a faster onset of action than vilanterol or salmeterol, which some patients appreciate.
If you have COPD and need more than what a two-drug inhaler provides, Trelegy Ellipta adds a third medication — an anticholinergic (LAMA) — to the same ingredients found in Breo Ellipta.
Trelegy Ellipta is a step up in therapy, not a direct substitute. Your doctor might recommend it if your COPD isn't well-controlled on a two-drug combination.
The best alternative for you depends on several factors:
Your doctor and pharmacist are your best resources for choosing an alternative that fits your needs and budget.
Not being able to fill your Breo Ellipta prescription is frustrating, but it doesn't mean you have to go without effective treatment. Alternatives like Wixela Inhub, Advair, and Symbicort are proven ICS/LABA combinations that have helped millions of patients manage asthma and COPD.
If you'd like to try finding Breo Ellipta in stock before switching, use Medfinder to check real-time availability at pharmacies near you. And for more on how Breo Ellipta works, check out How Does Breo Ellipta Work? Mechanism of Action Explained.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.